Florian. Thanks,
advancing new in Christian pipeline rest towards As XXXX, and our a have technologies trials two clinic. truly time exciting year, rapidly to added last we've mentioned, completed atai. Florian new we're the important we're three growing start drug We the five at Since and of our portfolio. development and of the here programs
potentially year cognitive many and including pipeline data our this therapy for formulation schizophrenia, shown next. concept Phase in many from The use this to groundbreaking, our for our across on this As to impairment health, proof disorder, is study Later eagerly at-home, comparative ongoing key that indications generalized year, targets deep depression, pipeline this result the post-traumatic disorder we're clinical I acting We readouts a intend Phase important believe formulation bridge slide, stress anxiety TRD. mental PCN-XXX. a be PCN-XXX. to and a treatment supporting anticipating we with rapid of bioavailability associated opioid subcutaneous conclude In formulation will advancement This of IIa IV in use. to will resistant at-home from of disorder. trial XXXX,
our We continued expect other advancement clinical in programs.
We short a six have across XXXX. we Phase trial XXXX to I an we a of number trial and time. milestones readout initiation I expect at I really initiated trial amazing in Revixia. We've a and readouts total, obtain That's for trial In trial I II also Phase and period four Phase Phase of IIa anticipate EmpathBio, and Phase and initiations of Viridia Phase Kures GRX-XXX.
second schizophrenia, disability are the or associated Schizophrenia a list cognitive impairments of on worldwide to cognitive CIAS. this The the approved currently is with ubiquitous essentially program with treatments cause primarily that marked impairment due and targeting for condition. no There are CIAS. associated leading is
in trials cognitive are previously a model Phase II shown I Data RL-XXX, the challenge, is effects I pro used from involved and scopolamine Recognify This Sciences, cognitive trial observed with of study tested treatment modulator two glutamate cholinergic condition. a widely to one company, trials date nine receptor Our RL-XXX has and developing conducted this here. debilitating a of in the clinical for clinical Life third-party platform impairment. GABA Phase been trial. Phase
with Benefits shown dose higher beneficial the present the in on only of by The memory dose by as deficits the shown this absent on XX left, improved on as U-shaped and effects circles induced were at Some graphs. including attention, inverted by the curve. doses, challenge, an right verbal highlighted of response the milligram two the consistent were RL-XXX. were coadministration
alterations Importantly, or EEG quantitative this on pro cognitive effect was associated qEEG. with
immediate found was a target frequencies, large with recently, are memory. pain, in trial hand the impact that to higher previously. relative of domain Specifically, II spectral for cognitive The was shown in which of in biomarker longstanding thus cognitive to the the of it RL-XXX the sides vasculature. This we graph. peripheral diabetic conducted effects, the and brain as Again, XXX of condition shown were on with associated was from More on neuropathic lower right subclinical left results patients These a this Phase of impairments diabetes benefit providing notably I saw is a due seen pro verbal I both consistent and shift here. Phase mentioned results delayed induced recall, results engagement. with the previous trial often
patients last on dose the As consistent graphs, of dose at with demonstrated single RL-XXX the of benefit are here. In December outcome study, seen conducted again, announced inverted year, this pro arm, clinically we an with in level, summarized Phase on you was lower effects. curve. CIAS. XX-patient cognitive of blind the of this U-shaped response mechanism trial proof Building see single only successful RL-XXX The our studies, study IIa can the meaningful in these of results
studies. XX in Battery the Cognitive to MATRICS most U-shaped are can doses Consensus a of dependent was on are at highly effects Symbol several that we milligrams. you seen total beneficial correlates see, started the wane cognitive earlier with As Coding with improvements cognitive XX the the score. consistent These pronounced dose measures of inverted measure milligram test, the assessed. were there dose function This and on broad at The response that evident data XX and
show move concept measures. results to into a results, show initiate challenge. study This Phase the trial. on of to these Phase involving in trial changes the in larger trial randomized, consistent with on year. decided the Based that have were the placebo-controlled, scopolamine later exciting I we to the will Additionally, proof IIa previous powered We qEEG cognitive be plan improvements trials this
disability want and second depression, treatment worldwide. XXX Depression cause a to for million resistant I ranks globally, therapies or our affects TRD. on as potential leading of Next, people focus
effective This significant partly being of is third patient the to due the patients, certain inadequately are patients or treatments A current classified population. While TRD of likely are heterogeneity either patients a of as relapse. for resistant. percentage respond treatment
Let's development and first psilocybin. COMPXXX, of discuss formulation proprietary its Compass candidate, Pathways a
randomized, and this the mentioned, improvement. psychological consider Florian change was from is three Depression milligram XX on were resounding the p we achieve double-blind, single most or of This X.X The psilocybin primary milligrams Rating a to a robustly ever administration results or Most mild severity. durable moderate With patients, MADRS. and be X than MADRS and COMPXXX endpoint met. XXX was most either based As Scale, the conducted. approvals X with compared in of point baseline XX dose, being to trial When trial in The week treatment trial a a X reduction was improvement when coadministered Phase less languages, of support that largest, generally as remarkable a compound tolerated less. dose-controlled of complex on IIb logistically to classified X.XXX, the at success. Spanning events sites Montgomery-Åsberg this a rapid demonstrate the depression COMPXXX in adverse XX% resulted a symptoms. with or recent over emergent well of value robust
home Phase to Neuroscience later a is kicking agent Looking and explored dose meaning over in well a an study were FDA properties, for was II end being it of of glutamatergic is R-ketamine has with R-ketamine completed Perception scheduled tolerated the year. treatment Phase the R-ketamine XXXX. meeting anticipate TRD. A non-dissociated rapid range PCN-XXX, this late of They or The III was developed in acting events no for with forward, the off serious a at I formulation trial of developing unexpected adverse IV the have September Compass observed. April. as is Phase a use. antidepressant potential modulator
important XXXX, symptomatology placebo days Following consists subjects assessed patient of Data anticipated Positive burdens trial the in drug soon. this these patients in by PCN-XXX currently two initiated Phase patients results, subsequent In therapies current sites This double-blind, clearance parallel FDA. we be MADRS. from a one IV could This placebo-controlled of or in are Europe of year. the for DDI the with by sites or a this in new trial using Subjects the concept trial supports year, clinical we is of receive study as The September Phase this launching of of and will a Depressive intend of I across proof setting. active this US January of in successful doses which dose year. clearance XX conduct the the complete require for R-ketamine. application study, arms each. a end this will comes trial both be XX single of IIa significant results provider. announced rapid investigational our TRD. will This game-changing three with or to we administration and be
We completing study relative also year. I anticipate Phase bioavailability a this
the use. be previously, to bridge designed was at-home I subcutaneous this formulation This supporting of potential will IV a current formulation As key to one. trial to mentioned the
these programs, programs the clinical addition TRD year. In two clinic focused have this on we to preclinical entering
or of is Sciences, DMT. company, Life N,N-dimethyltryptamine formulation VLS-XX, developing a Our platform Viridia
Salvinorin Revixia unique pharmacologically Sciences both is In addition, We I this compounds psychedelic our plan RLS-XX. Life trials year. A, of compound. these developing later a to is formulation initiate a company Phase with platform This
drug urgent a these candidates of unique a TRD, heterogeneous four for So we for need represent with exciting in TRD indication total innovation. an have options pharmacologically of Together range pipeline. treatment our a
anxiety. to Turning
is Anxiety first with XXXX etifoxine in of the GRX-XXX etifoxine, disorder most anxiety developing TSPO compound data GABA without their sedation, a post neurosteroids are significant for Let's disorders. form therapeutics France treatment ataxia. as in the act increasing agonist, to of rapid Recent that but anxiety. approved the or production is diagnosed has acting, treatment demonstrated allopregnanolone. Pharmacologically, benzodiazepines, Etifoxine of million of surveillance we're thought like placebo-controlled of impairment an cognitive is analysis anxiety people like I talk Phase which one-third about of with for marketing lives. unlike benzodiazepines, a dependence. of we the associated or prevalent that at double-blind, GRX-XXX. disorders deuterated encompassing point some GRX-XXX, not over abuse trial a health a It's initiated was estimated mental of In in XXXX, is etifoxine, are randomized, June prescriptions disorders. approximately XX
the allopregnanolone in target Phase pharmacodynamics as biomarker, increase we're multiple related with spectral the for a It's this we a of the tolerability, and at of outlined GRX-XXX. As mechanism of using safety, changes band. the trial They trial. on noted that upon bottom slide, in a PK focusing were relative Based been study ascending and engagement compound, compounds. I power single conducted qEEG and looking dose also is have of etifoxine in action this the Such beta IV XXXX. demonstrated of
component with single the of trial the at potentially anxiety trial much initiating Phase SSRIs, patients excited of a ascending completed IIa of entirety multiple line of the a proof benzodiazepines ongoing. offering is We We're improved year. GRX-XXX of anticipate trial dose have best and treatment later I new the XXXX. the combining of expected are Phase by dose prospect the the We this middle and ascending for characteristics element the concept Top option. and
trial was compound. the of PK which of ibogaine, efficacy we of to I/IIa developing DMX-XXXX. safety, compounds In OED-focused trial. here move an oral the Both to disorder, occurring psychedelic naturally OUD, of our we'll the designed in assess DMX-XXXX, presently use challenge, IB, opioid first and September, Next Phase within combined or DemeRx trials. I X particularly At US. dosed Phase a subject tolerability, in we're health on Phase are a clinical formulation This component a major is
portion eagerly to of obtain We data trial anticipating. from that Phase we're expect I year, later the results safety this this
modulator which opioid of tolerated an is active is moiety better and considered thought developing OUD-focused mitragynine. is Our is This the compound, that in be second receptor in safer opioids. a atypical KUR-XXX, company, classical deuterated to kratom, form Kures,
that month. I Phase of the first study I earlier initiated of will end or These company this company Our new subject are AI-based II. discovery founded This focused the In remarkable three-and-a-half dosed to Phase only Invyxis, ascending stage approach a year, in trial computational respectively. is two year, dose this we of programs. this the past development. This the EntheogeniX, On is to we've They expected TryptageniX in by two KUR-XXX was read out medicinal a years Phase By companies single old. XX year. targeting a is chemistry the year, which have added achievement with chemistry NCE the subsidiaries, of our and on end compounds we bio-prospecting and XXXX. for supplement
these years more atai incorporating in approach, the even boasts platforms our together, will therapies are unique pipeline robust that three be of discovery means the engines of discovery in a with innovative Taken CNS. to platforms, These come. to one that the most each expansion crucial
analysis to key clinically our Our in digital in therapeutics, or multimodal collection efforts integral mental health. patients. are ongoing and and meaningful elements DTx, and precision changes digital DTx data data elements concerning of achieving strategy behavioral are support sustained and
ultimately undergoing Introspect provide therapy. a the Therapeutics, on acceptability trial launched administration. With to app-based March that personalized We user support Introspect were participants In therapeutics to of for we're psychedelic therapeutics improve interface treatments to and guide based developing ketamine safety, are Psyber, digital patient XXXX, focused efficacy we scalability With Digital to outcomes. digital brain developing our a digital improve computer are compounds.
data of data novel patients ultimately biological supporting synthesizes health. analytics phenotypic our for generation characterization in for to Analysis the data of Finally, may mental allow digital, better and indications. biomarkers, our platform of goal of our target precision these allow
very a achieved. immensely come our company, long have that in way I'm and of public years of We all first proud we've
With will innovative extremely have upcoming products. meaningful edge the turn the an highlights position mental now to strong robust milestones, for These of pipeline, over Greg? put us disorders. achieve our our in and data to health We ultimately, highly in overview patients platforms clinical cutting make programs particularly a a call lives of and I digital Greg and with that, discovery financial difference an
